tiprankstipranks
PepGen to Participate in Upcoming Investor Conferences
PremiumPress ReleasesPepGen to Participate in Upcoming Investor Conferences
4M ago
PepGen receives Orphan Drug, Rare Pediatric Disease designations for PGN-EDO51
PremiumThe Fly
PepGen receives Orphan Drug, Rare Pediatric Disease designations for PGN-EDO51
4M ago
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
PremiumPress Releases
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
4M ago
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
PremiumPress ReleasesPepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
5M ago
PepGen announces clearance of CTA by U.K. MHRA to begin CONNECT2-EDO51
PremiumThe Fly
PepGen announces clearance of CTA by U.K. MHRA to begin CONNECT2-EDO51
5M ago
PepGen Earns FDA Fast Track Status for Myotonic Dystrophy Drug
PremiumCompany Announcements
PepGen Earns FDA Fast Track Status for Myotonic Dystrophy Drug
5M ago
PepGen prices 7.53M shares at $10.635 in underwritten public offering
PremiumThe FlyPepGen prices 7.53M shares at $10.635 in underwritten public offering
6M ago
PepGen Inc trading resumes
PremiumThe Fly
PepGen Inc trading resumes
6M ago
PepGen Inc trading halted, volatility trading pause
PremiumThe Fly
PepGen Inc trading halted, volatility trading pause
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100